# Assembly Biosciences, Inc (ASMB)

> Assembly Biosciences, Inc (ASMB) trades at $19.85 (-0.35%) as of 3:57:22 PM EST on Nov 4, 2026, -10.50% over the past month. Market cap is $405.58M, with 11.1 days to cover in short interest.

Canonical: https://massive.com/quote/asmb
Data as of: 2026-11-04T20:57:22.791Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$19.85** -0.07 (-0.35%)
As of 3:57:22 PM EST on Nov 4, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Assembly Biosciences, Inc (ASMB) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -0.35% |
| 1W | -3.50% |
| 1M | -10.50% |
| YTD | -41.63% |
| 1Y | -38.18% |
| 52-wk range | $19.25 – $39.71 |

From daily closes through Nov 4, 2026.

## Key statistics

Today's trading snapshot for ASMB: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $19.58 – $20.55 |
| Open | $20.32 |
| Prev close | $19.92 |
| Volume | 195.9K |
| Market cap | $405.58M |
| Shares out | 20.36M |

## Valuation and profitability ratios

Valuation and profitability ratios for Assembly Biosciences, Inc: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 5.42 |
| P/B | 1.33 |
| P/FCF | — |
| ROE | -0.0% |
| ROA | -0.0% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 3, 2026

## Insider trading

[Assembly Biosciences, Inc (ASMB) insider trading](https://massive.com/quote/asmb/insider-trading.md): open-market Form 4 buys and sells by Assembly Biosciences, Inc insiders over the last 12 months.

## 8-K filings

Material corporate events Assembly Biosciences, Inc has disclosed to the SEC on Form 8-K.

- Jun 5, 2026 · Annual meeting results
  “On June 4, 2026, the matters listed below were submitted to a vote of the Company's stockholders at the Annual Meeting through the solicitation of proxies. The stockholders elected of the following to serve on the Company's Board of Directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified: Anthony E. Altig; Tomas Cihlar, Ph.D.; Gina Consylman; Robert D. Cook II; Sir Michael Houghton, Ph.D.; Lisa R. Johnson-Pratt, M.D.; Susan Mahony, Ph.D.; John G. McHutchison, A.O., M.D.; and Jason A. Okazaki.”
- May 26, 2026 · Warrant or conversion
  “The Company granted the Underwriters a 30-day option to purchase up to 566,040 additional shares of Common Stock on the same terms as the Offering Shares, and the Underwriters exercised the option in full on May 22, 2026. Pre-Funded Warrants to purchase up to an aggregate of 415,000 shares of Common Stock were issued with an initial exercise price of $0.001 per share and became immediately exercisable on the date of issuance.”
- May 22, 2026 · Product or service launch
  “Assembly Biosciences, Inc. (the 'Company') issued a press release announcing its plans to expand the clinical development of ABI-6250 ('6250'), its oral entry inhibitor candidate for chronic hepatitis delta virus ('HDV') infection, into primary biliary cholangitis ('PBC') and primary sclerosing cholangitis ('PSC'), broadening the program into cholestatic liver diseases.”
- Mar 30, 2026 · Executive compensation change
  “Also on March 24, 2026, the Committee approved an increase to the bonus target for Jason A. Okazaki, the Company's Chief Executive Officer and President, from 60% to 65% of his base salary (the 'Bonus Target Increase'), which is reflected in Amendment No. 1 to Mr. Okazaki's employment agreement. The Bonus Target Increase is effective for fiscal year 2026.”
- Dec 8, 2025 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “The Company announced interim results from the Phase 1b portions of its ongoing Phase 1a/b clinical studies evaluating ABI-1179 and ABI-5366, both investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates for recurrent genital herpes. For ABI-1179, a 98% reduction in HSV-2 shedding rate compared to placebo (p\<0.01) was observed with the 50 mg weekly dose, and a 91% reduction in virologically confirmed genital lesion rate was observed.”

## Dividend history and stock splits

Assembly Biosciences, Inc's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-12 · Feb 12, 2024

## ASMB short interest

How heavily ASMB is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 11.1 |
| Short interest | 2.91M |
| Avg volume | 263.1K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## ASMB news

The latest news and headlines about Assembly Biosciences, Inc (ASMB).

- [Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks](https://www.zacks.com/stock/news/2986964/oil-surge-continues-on-escalating-middle-east-crisis-4-defensive-picks?cid=CS-ZC-FT-analyst_blog|investment_ideas-2986964) · Zacks Investment Research · Sep 9, 2026 · positive sentiment
- [Assembli to Produce Big Ten Conference Activation at Fanatics Fest in New York](https://www.globenewswire.com/news-release/2026/07/16/3328740/0/en/Assembli-to-Produce-Big-Ten-Conference-Activation-at-Fanatics-Fest-in-New-York.html) · GlobeNewswire Inc. · Jul 16, 2026 · positive sentiment
- [Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference](https://www.globenewswire.com/news-release/2026/05/11/3291802/16259/en/Assembly-Biosciences-to-Present-at-the-BofA-Securities-2026-Global-Health-Care-Conference.html) · GlobeNewswire Inc. · May 11, 2026 · positive sentiment
- [Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights](https://www.globenewswire.com/news-release/2026/05/07/3290491/16259/en/Assembly-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Recent-Highlights.html) · GlobeNewswire Inc. · May 7, 2026 · positive sentiment
- [Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results](https://www.globenewswire.com/news-release/2025/05/21/3085649/0/en/Assembly-s-NeosAI-Powered-by-Microsoft-Azure-AI-Foundry-Sets-New-Benchmark-for-Legal-Productivity-Backed-by-Real-World-Results.html) · GlobeNewswire Inc. · May 21, 2025 · positive sentiment

## About Assembly Biosciences, Inc

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 73 |
| Listed | Dec 17, 2010 |

[Company website](https://www.assemblybio.com)

## FAQ

### What is the Assembly Biosciences, Inc (ASMB) stock price today?

Assembly Biosciences, Inc (ASMB) is trading at $19.85 (-0.35% on the day) as of 3:57:22 PM EST on Nov 4, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Assembly Biosciences, Inc?

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally…

### What is the short interest in ASMB?

As of Oct 15, 2026, ASMB has 2.91M shares short and 11.1 days to cover.

### What exchange is ASMB listed on?

Assembly Biosciences, Inc (ASMB) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ASMB quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ASMB`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Assembly Biosciences, Inc (ASMB) insider trading](https://massive.com/quote/asmb/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms